menu
    • menu
    [{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Aerpio Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Merger","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aadi Bioscience \/ Aerpio Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Aadi Bioscience \/ Aerpio Pharmaceuticals"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Foundation Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Collaboration","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aadi Bioscience \/ Foundation Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Aadi Bioscience \/ Foundation Medicine"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Acuta Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Private Placement","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aadi Bioscience \/ Acuta Capital Partners","highestDevelopmentStatusID":"15","companyTruncated":"Aadi Bioscience \/ Acuta Capital Partners"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Aerpio Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Merger","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aadi Bioscience \/ Aerpio Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Aadi Bioscience \/ Aerpio Pharmaceuticals"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Avoro Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Private Placement","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aadi Bioscience \/ Avoro Capital","highestDevelopmentStatusID":"15","companyTruncated":"Aadi Bioscience \/ Avoro Capital"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Eoc Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Collaboration","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aadi Bioscience \/ Eoc Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Aadi Bioscience \/ Eoc Pharma"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Adagrasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Preclinical","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aadi Bioscience \/ Mirati Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Aadi Bioscience \/ Mirati Therapeutics"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aadi Bioscience \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aadi Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"||mTOR","graph1":"Oncology","graph2":"Preclinical","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aadi Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Aadi Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Phase II","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aadi Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aadi Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Phase II","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aadi Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aadi Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aadi Bioscience \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aadi Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aadi Bioscience \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aadi Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aadi Bioscience \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aadi Bioscience \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Aadi Bioscience

    Menu

    Aadi Bioscience

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Aadi Bioscience

    U.S.A arrow
    BioTrinity 2025
    Not Confirmed

    Aadi Bioscience

    U.S.A arrow
    BioTrinity 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Adagrasib,Nab-Sirolimus

    Therapeutic Area : Oncology

    Study Phase : Preclinical

    Sponsor : Mirati Therapeutics

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    Mirati Therapeutics and Aadi Bioscience Partner to Evaluate the Combination of Adagrasib with Nab-sirolimus in...

    Details : Under the terms of the collaboration agreement, Mirati will be responsible for sponsoring and operating the Phase 1/2 study of Adagrasib (MRTX849), and jointly with Aadi, will oversee and share the cost of the study.

    Product Name : MRTX849

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    December 10, 2022

    Lead Product(s) : Adagrasib,Nab-Sirolimus

    Therapeutic Area : Oncology

    Highest Development Status : Preclinical

    Sponsor : Mirati Therapeutics

    Deal Size : Undisclosed

    Deal Type : Partnership

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Aadi Bioscience

    U.S.A arrow
    BioTrinity 2025
    Not Confirmed

    Aadi Bioscience

    U.S.A arrow
    BioTrinity 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Sirolimus,Adagrasib

    Therapeutic Area : Oncology

    Study Phase : Preclinical

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at...

    Details : ABI-009 (Nab-sirolimus) is a novel albumin-bound nanoparticle form of the mTOR inhibitor sirolimus and is approved for the treatment of locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

    Product Name : Fyarro

    Product Type : Antibiotic

    Upfront Cash : Inapplicable

    October 27, 2022

    Lead Product(s) : Sirolimus,Adagrasib

    Therapeutic Area : Oncology

    Highest Development Status : Preclinical

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Aadi Bioscience

    U.S.A arrow
    BioTrinity 2025
    Not Confirmed

    Aadi Bioscience

    U.S.A arrow
    BioTrinity 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Sirolimus

    Therapeutic Area : Oncology

    Study Phase : Phase II

    Sponsor : Avoro Capital

    Deal Size : $72.5 million

    Deal Type : Private Placement

    DEALS_DEV arrow-down

    Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing

    Details : The company intends to use net proceeds from the financing to fund research and development of Nab-sirolimus and additional clinical opportunities with FYARRO and for working capital and general corporate purposes.

    Product Name : Fyarro

    Product Type : Antibiotic

    Upfront Cash : Undisclosed

    September 22, 2022

    Lead Product(s) : Sirolimus

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Sponsor : Avoro Capital

    Deal Size : $72.5 million

    Deal Type : Private Placement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Aadi Bioscience

    U.S.A arrow
    BioTrinity 2025
    Not Confirmed

    Aadi Bioscience

    U.S.A arrow
    BioTrinity 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Sirolimus

    Therapeutic Area : Oncology

    Study Phase : Phase II

    Sponsor : Foundation Medicine

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders

    Details : Partners will collect and analyze clinical and molecular data to determine which patients may be eligible to participate in Aadi’s PRECISION 1 clinical trial for ABI-009. The goals are to increase patient match rate, reduce screen failure rate and incr...

    Product Name : Fyarro

    Product Type : Antibiotic

    Upfront Cash : Undisclosed

    September 05, 2022

    Lead Product(s) : Sirolimus

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Sponsor : Foundation Medicine

    Deal Size : Undisclosed

    Deal Type : Collaboration

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    Aadi Bioscience

    U.S.A arrow
    BioTrinity 2025
    Not Confirmed

    Aadi Bioscience

    U.S.A arrow
    BioTrinity 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Sirolimus

    Therapeutic Area : Oncology

    Study Phase : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Aadi Bioscience Announces Data Presentation on incidence of TSC1 and TSC2 Alterations in Advanced Cancers at t...

    Details : Based on data from the AMPECT trial with FYARRO and following discussions with the FDA about other emerging data with FYARRO, Aadi has initiated PRECISION 1, a tumor-agnostic registrational trial in mTOR inhibitor-naïve solid tumors.

    Product Name : Fyarro

    Product Type : Antibiotic

    Upfront Cash : Inapplicable

    August 04, 2022

    Lead Product(s) : Sirolimus

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    06

    Aadi Bioscience

    U.S.A arrow
    BioTrinity 2025
    Not Confirmed

    Aadi Bioscience

    U.S.A arrow
    BioTrinity 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Sirolimus

    Therapeutic Area : Oncology

    Study Phase : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Pro...

    Details : Nab-sirolimus is an albumin-bound mTOR inhibitor approved by the U.S. Food and Drug Administration (FDA) as FYARRO™ for the treatment of adult patients with locally advanced unresectable or metastatic malignant PEComa.

    Product Name : Fyarro

    Product Type : Antibiotic

    Upfront Cash : Inapplicable

    May 26, 2022

    Lead Product(s) : Sirolimus

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    07

    Aadi Bioscience

    U.S.A arrow
    BioTrinity 2025
    Not Confirmed

    Aadi Bioscience

    U.S.A arrow
    BioTrinity 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Sirolimus

    Therapeutic Area : Oncology

    Study Phase : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Aadi Bioscience Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus...

    Details : FYARRO is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

    Product Name : Fyarro

    Product Type : Antibiotic

    Upfront Cash : Inapplicable

    March 31, 2022

    Lead Product(s) : Sirolimus

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    08

    Aadi Bioscience

    U.S.A arrow
    BioTrinity 2025
    Not Confirmed

    Aadi Bioscience

    U.S.A arrow
    BioTrinity 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Sirolimus

    Therapeutic Area : Oncology

    Study Phase : Phase II

    Sponsor : Eoc Pharma

    Deal Size : $271.0 million

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Aadi Bioscience and EOC Pharma Announce License and Collaboration Agreement for ABI-009 (FYARRO) in Greater Ch...

    Details : Under the terms of the agreement, EOC Pharma will obtain exclusive rights to develop and commercialize ABI-009 in Greater China.

    Product Name : Fyarro

    Product Type : Antibiotic

    Upfront Cash : Undisclosed

    November 01, 2021

    Lead Product(s) : Sirolimus

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Sponsor : Eoc Pharma

    Deal Size : $271.0 million

    Deal Type : Collaboration

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    09

    Aadi Bioscience

    U.S.A arrow
    BioTrinity 2025
    Not Confirmed

    Aadi Bioscience

    U.S.A arrow
    BioTrinity 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Sirolimus

    Therapeutic Area : Oncology

    Study Phase : Approved FDF

    Sponsor : Acuta Capital Partners

    Deal Size : $155.0 million

    Deal Type : Private Placement

    DEALS_DEV arrow-down

    Aadi Bioscience Announces Closing of Merger with Aerpio Pharmaceuticals and $155M Private Placement

    Details : Proceeds from the PIPE financing are expected to be used for the commercialization of FYARRO in advanced malignant PEComa, a planned tumor-agnostic registrational trial in solid tumors harboring inactivating alterations in the mTOR pathway genes TSC1 and...

    Product Name : Fyarro

    Product Type : Antibiotic

    Upfront Cash : Undisclosed

    August 26, 2021

    Lead Product(s) : Sirolimus

    Therapeutic Area : Oncology

    Highest Development Status : Approved FDF

    Sponsor : Acuta Capital Partners

    Deal Size : $155.0 million

    Deal Type : Private Placement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    10

    Aadi Bioscience

    U.S.A arrow
    BioTrinity 2025
    Not Confirmed

    Aadi Bioscience

    U.S.A arrow
    BioTrinity 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Sirolimus

    Therapeutic Area : Oncology

    Study Phase : Phase II

    Sponsor : Aerpio Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Merger

    DEALS_DEV arrow-down

    Aadi Bioscience Announces Closing of Merger with Aerpio Pharmaceuticals and $155M Private Placement

    Details : The combined, publicly traded company will focus on the advancement, expansion and commercialization of Aadi’s clinical stage pipeline, including Aadi’s lead program for its nanoparticle albumin-bound mTOR inhibitor, FYARRO™, an mTOR inhibitor boun...

    Product Name : Fyarro

    Product Type : Antibiotic

    Upfront Cash : Undisclosed

    August 26, 2021

    Lead Product(s) : Sirolimus

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Sponsor : Aerpio Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Merger

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth